Publication:
Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).

dc.contributor.authorGudiol, C
dc.contributor.authorNicolae, S
dc.contributor.authorRoyo-Cebrecos, C
dc.contributor.authorAguilar-Guisado, M
dc.contributor.authorMontero, I
dc.contributor.authorMartin-Gandul, C
dc.contributor.authorPerayre, M
dc.contributor.authorBerbel, D
dc.contributor.authorEncuentra, M
dc.contributor.authorArnan, M
dc.contributor.authorCisneros-Herreros, J M
dc.contributor.authorCarratala, J
dc.contributor.funderInstituto de Salud Carlos III, Spanish Ministry of Economy
dc.contributor.funderNetwork for Research in Infectious Diseases (REIPI )
dc.contributor.funderFEDER funds/European Regional Development Fund (ERDF)
dc.date.accessioned2023-01-25T10:07:47Z
dc.date.available2023-01-25T10:07:47Z
dc.date.issued2018-05-02
dc.description.abstractCatheter-related bloodstream infection (CRBSI) is one of the most frequent complications in patients with cancer who have central venous catheters (CVCs) implanted and is associated with substantial morbidity and mortality. Taurolidine is a non-antibiotic agent with broad-spectrum antimicrobial activity, which has been used as a lock solution to prevent CRBSI in some settings. However, little is known about its usefulness in high-risk adult neutropenic patients with cancer. This prospective randomised clinical trial aims to test the hypothesis that taurolidine-citrate lock solution is more effective than placebo for preventing catheter infection in neutropenic haematological patients. This study is a prospective, multicentre, randomised, double-blinded, parallel, superiority, placebo-controlled trial. Patients with haematological cancer who are expected to develop prolonged neutropenia (> 7 days) and who have a non-tunnelled CVC implanted will be randomised to receive prophylactic taurolidine-citrate-heparin solution using a lock technique (study group) or heparin alone (placebo group). The primary endpoint will be bacterial colonisation of the CVC hubs. The secondary endpoints will be the incidence of CRBSI, CVC removal, adverse events, and 30-day case-fatality rate. The lock technique is a preventive strategy that inhibits bacterial colonisation in the catheter hubs, which is the initial step of endoluminal catheter colonisation and the development of infection. Taurolidine is a nontoxic agent that does not develop antibiotic resistance because it acts as an antiseptic rather than an antibiotic. Taurolidine has shown controversial results in the few trials conducted in cancer patients. These studies have important limitations due to the lack of data on adult and/or high-risk neutropenic patients, the type of catheters studied (tunnelled or ports), and the lack of information regarding the intervention (e.g. dwelling of the solution, time, and periodicity of the lock technique). If our hypothesis is proven, the study could provide important solid evidence on the potential usefulness of this preventive procedure in a population at high risk of CRBSI, in whom this complication may significantly impair patient outcome. ISRCTN, ISRCTN47102251 . Registered on 9 September 2015.
dc.description.versionSi
dc.identifier.citationGudiol C, Nicolae S, Royo-Cebrecos C, Aguilar-Guisado M, Montero I, Martín-Gandul C, et al. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT). Trials. 2018 May 2;19(1):264.
dc.identifier.doi10.1186/s13063-018-2647-y
dc.identifier.essn1745-6215
dc.identifier.pmcPMC5932813
dc.identifier.pmid29720244
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932813/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1186/s13063-018-2647-y
dc.identifier.urihttp://hdl.handle.net/10668/12414
dc.issue.number1
dc.journal.titleTrials
dc.journal.titleabbreviationTrials
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number10
dc.provenanceRealizada la curación de contenido 11/03/2025
dc.publisherBioMed Central Ltd.
dc.pubmedtypeClinical Trial Protocol
dc.pubmedtypeJournal Article
dc.relation.projectIDPI13/01474
dc.relation.projectIDREIPI RD12/0015
dc.relation.publisherversionhttps://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2647-y
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAntibiotic lock technique
dc.subjectCatheter-related bloodstream infection
dc.subjectCentral venous catheter infection
dc.subjectHaematological patients
dc.subjectLock solution
dc.subjectNeutropenia
dc.subjectTaurolidine-citrate
dc.subject.decsCatéteres
dc.subject.decsNeoplasias
dc.subject.decsMétodos
dc.subject.decsAntibacterianos
dc.subject.decsHeparina
dc.subject.decsNeutropenia
dc.subject.decsSepsis
dc.subject.decsFarmacorresistencia microbiana
dc.subject.meshAnti-Infective Agents
dc.subject.meshAntineoplastic Agents
dc.subject.meshCatheter-Related Infections
dc.subject.meshCatheterization, Central Venous
dc.subject.meshCatheters, Indwelling
dc.subject.meshCentral Venous Catheters
dc.subject.meshCitrates
dc.subject.meshDevice Removal
dc.subject.meshDouble-Blind Method
dc.subject.meshEquivalence Trials as Topic
dc.subject.meshHematologic Neoplasms
dc.subject.meshHumans
dc.subject.meshMulticenter Studies as Topic
dc.subject.meshNeutropenia
dc.subject.meshProspective Studies
dc.subject.meshRisk Factors
dc.subject.meshSpain
dc.subject.meshTaurine
dc.subject.meshThiadiazines
dc.subject.meshTime Factors
dc.subject.meshTreatment Outcome
dc.titleAdministration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number19
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
PMC5932813.pdf
Size:
1006.42 KB
Format:
Adobe Portable Document Format
No Thumbnail Available
Name:
Gudiol_AdministrationOf _MaterialSuplementario.docx
Size:
36.6 KB
Format:
Microsoft Word XML